A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2018

At a glance

  • Drugs NIR 178 (Primary) ; Spartalizumab (Primary)
  • Indications Breast cancer; Colon cancer; Diffuse large B cell lymphoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 02 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2017 Planned number of patients changed from 300 to 260.
    • 16 Aug 2017 Planned initiation date changed from 18 Aug 2017 to 8 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top